Please assess the completion status of the following clinical trial:

Trial Title: Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.~* Moderate to severe chronic plaque psoriasis at both Screening and Baseline (Randomization) Visits~* Candidates for systemic therapy or phototherapy for psoriasis treatment as assessed by the investigator~Exclusion Criteria:~* Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19 inhibitor~* Concurrent therapy with a biologic and/or other systemic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for risankizumab by subcutaneous (SC) injection.
- Risankizumab (Type: EXPERIMENTAL): Risankizumab by subcutaneous (SC) injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).